Eric Li | Chief Scientific Officer
Luxena Pharmaceuticals

Eric Li, Chief Scientific Officer, Luxena Pharmaceuticals

Eric Li, Ph.D. — Chief Scientific Officer. Eric has extensive R&D and regulatory experiences in Oncology, Neurology, Metabolic Diseases, Molecular Mechanism of Therapeutic Approaches, and Biomedical Engineering.  Eric got his Ph.D. in Biochemistry, Molecular and Cell Biology from University of Rochester School of Medicine and Dentistry.  Past experiences include MAP Pharmaceuticals (Inhaled DHE for migraine), NeurogesX (Capsaicin Patch), Hana Biosciences (Liposomal Vincristine), and National Institutes of Health (Breast Cancer).


World Orphan Drug Congress USA 2018 - Conference Day Two @ 14:20

Orally Inhaled Ondansetro for the prevention of chemotherapy-induced nausea and vomiting due to highly emetogenic chemotherapy in pediatric patients

back to speakers